卵巢癌患者血清GDF15水平变化及其临床意义-现代医学

卵巢癌患者血清GDF15水平变化及其临床意义

单位：广东省韶关市粤北人民医院检验科, 广东韶关 512026

分类号：R737.3

出版年·卷·期（页码）：2020·39·第七期（828-832）

摘要：

目的：研究血清生长分化因子15（GDF15）水平的变化与卵巢肿瘤临床病理特征的关系及对卵巢癌疗效、预后的评估价值。方法：以84 例初治卵巢癌手术患者（卵巢癌组）和81 例卵巢良性疾病患者（卵巢良性疾病组）作为研究对象。采用酶联免疫吸附法分别对两组患者的血清GDF15水平进行检测。分析两组患者治疗前后血清GDF15水平变化及与卵巢癌疗效、患者无进展生存期（PFS）及总生存期（OS）的关系。结果：卵巢癌组GDF15水平高于卵巢良性疾病组。血清GDF15水平与卵巢癌患者的FIGO临床分期、淋巴结转移及病理类型有关（P<0.05）。卵巢癌患者中血清低GDF15组中完全缓解率（43.66%）高于血清高GDF15组（17.81%），差异有统计学意义（P<0.05）。Kaplan-Meier生存曲线分析显示，血清低GDF15组患者5年OS和PFS分别为79.5%和69.2%，高于血清高GDF15组患者，差异有统计学意义（均P<0.05）。COX回归提示，治疗前高的血清GDF15水平、高的FIGO分期、有淋巴结转移为影响卵巢癌患者预后的危险因素（P<0.05，OR>1）。结论：血清GDF15表达水平与卵巢癌的发生发展、疗效评估和预后有关，对卵巢癌患者的诊治具有一定的临床指导作用。

Objective:To study the relationship between serum growth differentiation factor 15 (GDF15) level and the clinicopathological characteristics of ovarian tumors,and to evaluate the efficacy and prognosis of ovarian cancer. Methods: 84 patients with ovarian cancer(ovarian cancer group)who had undergone initial surgery and 81 patients with benign ovarian disease(benign ovarian disease group)were selected as the study subjects. The level of serum GDF15 in the two groups was detected by enzyme-linked immunosorbent assay. The relationship between serum GDF15 level and post-treatment efficacy, progression free survival (PFS) and overall survival (OS) wasanalyzed.Results: The level of GDF15 in ovarian cancer group washigher than that in benign ovarian disease group. The level of serum GDF15 was correlated with FIGO clinical stage, lymph node metastasis and pathological type in patients with ovarian cancer (P<0.05). Among ovarian cancer patients, the complete remission(CR) rate was 43.66% in the serum low GDF15 group, which was higher than 17.81% in the serum high GDF15 group (P<0.05).Kaplan-Meier survival analysis showed that the 5-year OS rate and PFS rate of patients in serum low GDF 15 group were 79.5% and 69.2% respectively, which werehigher than those of patients in serum high GDF15 group (all P<0.05).COX regression showed that high serum GDF15 level, high FIGO stage and lymph node metastasis before treatment were risk factors for prognosis of ovarian cancer patients (P<0.05, OR>1). Conclusion:The expression level of serum GDF15 is related to the occurrence, development, efficacy evaluation and prognosis prediction of ovarian cancer, which has a certain clinical guiding role in the diagnosis and treatment of ovarian cancer.

参考文献：

[1] 马晓洁,王倩,谭榜宪.卵巢癌肿瘤标志物联合检测新进展[J].现代医学,2015,43(3):395-398.
[2] ORR B,EDWARDS R P.Diagnosis and treatment of ovarian cancer[J].Hematol Oncol Clin North Am,2018,32(6):943-964.
[3] 李芳,吴素慧.HE4与妇科肿瘤相关性的研究进展[J].国际妇产科学杂志,2017,44(4):369-373.
[4] 廖胜斌,李力.CA125和人附睾蛋白4对预测卵巢上皮性癌治疗效果及预后的意义[J].中华妇产科杂志,2017,52(6):429-432.
[5] SOUCEK K,MALENOVSKA A,KAHOUNOVA Z,et al.Presence of growth/differentiation factor-15 cytokine in human follicular fluid,granulosa cells,and oocytes[J].J Assist Reprod Genet,2018,35(8):1407-1417.
[6] TSAI V W W,HUSAINI Y,SAINSBURY A,et al.The MIC-1/GDF15-GFRAL pathway in energy homeostasis:implications for obesity,cachexia,and other associated diseases[J].Cell Metab,2018,28(3):353-368.
[7] BAEK S J,ELING T.Growth differentiation factor 15(GDF15):A survival protein with therapeutic potential in metabolic diseases[J].Pharmacol Ther,2019,198(1):46-58.
[8] 刘智嘉,郭隽馥,张芮,等.生长分化因子15对人肺腺癌SPCA1细胞增殖与迁移的影响[J].中国肿瘤生物治疗杂志,2017,24(11):1336-1338.
[9] 林仲秋.FIGO/IGCS妇科恶性肿瘤分期及临床实践指南(6版):卵巢癌[J].国际妇产科学杂志,2008,35(6):459-461.
[10] EISENHAUER E A,VERWEIJ J,EISENHAUER E A,et al.11 New response evaluation criteria in solid tumors:RECIST GUIDELINE VERSION 1.1[J].Ejc Supplements,2009,7(2):5.
[11] 李玮,李然,朱根海,等.围手术期CA125水平对高级别浆液性卵巢癌的预后价值研究[J].东南大学学报(医学版),2019,38(5):877-880.
[12] 李博,张颖,辛晓燕.GDF15基因在卵巢上皮性癌组织中的表达及其临床意义[J].现代生物医学进展,2014,14(29):5665-5670.
[13] 牛贝贝,田瑛.GDF15在卵巢肿瘤中的研究进展[J].中国妇幼保健,2015,30(15):2473-2476.
[14] URAKAWA N,UTSUNOMIYA S,NISHIO M,et al.GDF15 derived from both tumor-associated macrophages and esophageal squamous cell carcinomas contributes to tumor progression via Akt and Erk pathways[J].Lab Invest,2015,95(5):491-503.
[15] LI C,WANG X,CASAL I,et al.Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer[J].J Cell Mol Med,2016,20(8):1420-1426.
[16] GUO L L,WANG S F.Downregulated long noncoding RNA GAS5 fails to function as decoy of CEBPB,resulting in increased GDF15 expression and rapid ovarian cancer cell proliferation[J].Cancer Biother Radiopharm,2019,34(8):537-546.
[17] KALLI M,MINIA A,PLIAKA V,et al.Solid stress-induced migration is mediated by GDF15 through Akt pathway activation in pancreatic cancer cells[J].Sci Rep,2019,9(1):978.
[18] 张博,张颖,牛力春,等.血清GDF15和CA125水平检测对上皮性卵巢癌患者的诊断价值[J].陕西医学杂志,2016,45(2):225-227.
[19] WANG X,YANG Z,TIAN H,et al.Circulating MIC-1/GDF15 is a complementary screening biomarker with CEA and correlates with liver metastasis and poor survival in colorectal cancer[J].Oncotarget,2017,8(15):24892-24901.
[20] 高湘玲.生长分化因子15在上皮性卵巢癌中的表达及临床意义[J].现代肿瘤医学,2017,25(9):1438-1441.
[21] ZHAO D,WANG X,ZHANG W.GDF15 predict platinum response during first-line chemotherapy and can act as a complementary diagnostic serum biomarker with CA125 in epithelial ovarian cancer[J].BMC Cancer,2018,18(1):328-331.
[22] MEIER J C,HAENDLER B,SEIDEL H,et al.Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis[J].Cancer Med,2015,4(2):253-267.
[23] STAFF A C,BOCK A J,BECKER C,et al.Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer[J].Gynecol Oncol,2010,118(3):237-243.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录